LifeMD (LFMD) financial statements
LifeMD reported revenue of $194M in fiscal 2025, up 49.4% a year over 9 years.
Net income was $14M and the operating margin -4.0%, against -22.4% in 2016.
Free cash flow was $6M, and the company returned $3M in dividends and $270,000 in net buybacks.
The diluted share count rose 574% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from LifeMD's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $4M | $8M | $12M | $37M | $93M | $119M | $153M | $209M | $194M |
| Cost of revenue | $2M | $1M | $2M | $3M | $9M | $18M | $19M | $19M | $24M | $28M |
| Gross profit | $3M | $3M | $6M | $10M | $28M | $75M | $100M | $134M | $185M | $166M |
| Selling, general and admin | $3M | $2M | $7M | $11M | $84M | $122M | $125M | $128M | $174M | $144M |
| Operating income | -$1M | -$1M | -$2M | -$3M | -$58M | -$54M | -$43M | -$14M | -$18M | -$8M |
| Interest expense | $48,611 | $100,523 | $354,388 | $761,150 | $2M | $3M | $1M | $3M | $2M | $1M |
| Pre-tax income | -$1M | -$1M | -$2M | -$4M | -$60M | -$61M | -$45M | -$17M | $20M | -$10M |
| Income tax | — | — | -$124,700 | -$122,500 | $122,500 | $7,700 | $360,700 | $428,000 | $402,000 | $45,721 |
| Net income | -$1M | -$1M | -$1M | -$3M | -$59M | -$61M | -$46M | -$21M | -$21M | $14M |
| EPS (diluted) | -$0.15 | -$0.15 | — | — | — | — | — | — | -$0.60 | $0.25 |
| Diluted shares | 7M | 8M | 9M | 10M | 14M | 27M | 31M | 34M | 41M | 45M |
| Gross margin | 62.9% | 72.4% | 76.0% | 79.7% | 76.2% | 80.6% | 84.3% | 87.6% | 88.5% | 85.7% |
| Operating margin | -22.4% | -33.4% | -24.7% | -23.2% | -155.0% | -58.5% | -36.5% | -9.5% | -8.8% | -4.0% |
| Net margin | -21.1% | -32.8% | -14.9% | -25.2% | -157.3% | -65.6% | -38.3% | -13.5% | -10.3% | 7.4% |
Balance sheet
Fiscal years, from LifeMD's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $182,561 | $141,379 | $180,093 | $1M | $9M | $41M | $4M | $33M | $35M | $37M |
| Receivables | $444,743 | $128,190 | $99,053 | $97,448 | $997,757 | $980,055 | $3M | $6M | $11M | $9M |
| Inventory | $160,270 | $681,258 | $1M | $950,059 | $1M | $2M | $4M | $3M | $3M | $3M |
| Total current assets | $789,824 | $1M | $2M | $3M | $12M | $45M | $11M | $43M | $52M | $52M |
| Property, plant and equipment | — | — | — | — | — | $233,805 | $476,441 | $476,303 | $1M | $2M |
| Goodwill | — | — | — | — | — | $0 | $8M | — | — | — |
| Total assets | $789,824 | $1M | $3M | $3M | $13M | $50M | $26M | $58M | $76M | $70M |
| Total current liabilities | $1M | $640,971 | $1M | $4M | $14M | $23M | $31M | $35M | $67M | $42M |
| Total liabilities | $1M | $640,971 | $2M | $5M | $14M | $24M | $33M | $53M | $84M | $47M |
| Shareholders' equity | -$355,170 | $881,923 | $897,700 | -$988,185 | -$2M | $23M | -$11M | $4M | -$9M | $23M |
| Net debt | -$182,561 | -$141,379 | -$180,093 | -$1M | -$9M | -$41M | -$4M | -$33M | -$35M | -$37M |
Cash flow
Fiscal years, from LifeMD's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$407,914 | -$817,216 | -$905,519 | $251,408 | -$12M | -$33M | -$23M | $9M | $18M | $8M |
| Capital spending | — | — | — | — | — | $247,365 | $366,633 | $203,814 | $1M | $2M |
| Free cash flow | — | — | — | — | — | -$33M | -$23M | $9M | $16M | $6M |
| Stock-based compensation | $587,991 | $162,741 | $273,570 | $733,215 | $19M | $12M | $14M | $12M | $12M | $10M |
| Dividends paid | — | — | — | — | — | $871,476 | $3M | $3M | $3M | $3M |
| Share buybacks (net) | — | -$76,648 | — | — | — | — | — | — | — | -$270,000 |
| Net borrowing | — | — | — | -$284,070 | — | $0 | — | — | — | -$19M |
| Free cash flow margin | — | — | — | — | — | -35.9% | -19.6% | 5.6% | 7.7% | 3.3% |
| Dividends per share | — | — | — | — | — | $0.03 | $0.10 | $0.09 | $0.08 | $0.07 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LFMD.
Open LFMD in InvestinglyQuestions
What was LifeMD's revenue in 2025?
$194M in fiscal 2025, from its 10-K filing.
How much free cash flow does LifeMD generate?
$6M in fiscal 2025 (operating cash flow minus capital spending).
From LifeMD's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.